(Z)-7-[(1R,2R,3R)-2-[(E)-(S)-5-(4-Bromo-5-methyl-thiophen-2-yl)-3-(tert-butyl-dimethyl-silanyloxy)-pent-1-enyl]-3-(tert-butyl-dimethyl-silanyloxy)-5-oxo-cyclopentyl]-hept-5-enoic acid methyl ester | 875910-25-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (Z)-7-[(1R,2R,3R)-2-[(E)-(S)-5-(4-Bromo-5-methyl-thiophen-2-yl)-3-(tert-butyl-dimethyl-silanyloxy)-pent-1-enyl]-3-(tert-butyl-dimethyl-silanyloxy)-5-oxo-cyclopentyl]-hept-5-enoic acid methyl ester
• 英文别名: methyl (Z)-7-[(1R,2R,3R)-2-[(E,3S)-5-(4-bromo-5-methylthiophen-2-yl)-3-[tert-butyl(dimethyl)silyl]oxypent-1-enyl]-3-[tert-butyl(dimethyl)silyl]oxy-5-oxocyclopentyl]hept-5-enoate
• CAS: 875910-25-1
• 化学式: C₃₅H₅₉BrO₅SSi₂
• 分子量: 727.991
• InChiKey: NWCGDVUJSPORES-RHRZYJIISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.58
• 重原子数：
  44
• 可旋转键数：
  18
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  90.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (Z)-7-[(1R,2R,3R)-2-[(E)-(S)-5-(4-Bromo-5-methyl-thiophen-2-yl)-3-(tert-butyl-dimethyl-silanyloxy)-pent-1-enyl]-3-(tert-butyl-dimethyl-silanyloxy)-5-oxo-cyclopentyl]-hept-5-enoic acid methyl ester 在 溶剂黄146 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 17.0h， 以51%的产率得到(Z)-7-{(1R,2S)-2-[(E)-(S)-5-(4-Bromo-5-methyl-thiophen-2-yl)-3-hydroxy-pent-1-enyl]-5-oxo-cyclopent-3-enyl}-hept-5-enoic acid methyl ester
  参考文献：
  名称：

  Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents

  摘要：

  一种化合物，包括或其药用可接受的盐或前药，其中A、B、R1、R2、D和E在此定义。用于治疗疾病的治疗方法，以及相关的组合物和药物也被披露。

  公开号：

  US20060035961A1
• 作为产物：
  描述：

  (Z)-7-[(1R,2R,3R,5S)-2-[(E)-(S)-5-(4-Bromo-5-methyl-thiophen-2-yl)-3-(tert-butyl-dimethyl-silanyloxy)-pent-1-enyl]-3-(tert-butyl-dimethyl-silanyloxy)-5-hydroxy-cyclopentyl]-hept-5-enoic acid methyl ester 在 四丙基高钌酸铵 、 N-甲基吗啉氧化物 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以84%的产率得到(Z)-7-[(1R,2R,3R)-2-[(E)-(S)-5-(4-Bromo-5-methyl-thiophen-2-yl)-3-(tert-butyl-dimethyl-silanyloxy)-pent-1-enyl]-3-(tert-butyl-dimethyl-silanyloxy)-5-oxo-cyclopentyl]-hept-5-enoic acid methyl ester
  参考文献：
  名称：

  Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents

  摘要：

  本文披露了一种含有所述详细描述的基团的化合物或其药学上可接受的盐或前药。本文还披露了包括其衍生物或药学上可接受的盐、四氮唑或所述结构物的前药的化合物。所述衍生物在此处详细描述。本文还披露了治疗疾病或病况的方法，包括青光眼和眼内压升高。还披露了与此相关的药物制剂的组成和制造方法。

  公开号：

  US20060035949A1

文献信息

• Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
  申请人：Donde Yariv

  公开号：US20060035961A1

  公开（公告）日：2006-02-16

  A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, wherein A, B, R 1 , R 2 , D, and E are defined herein. Use of the diseases for the treatment of diseases, and compositions and medicaments related thereto are also disclosed.

  一种化合物，包括或其药用可接受的盐或前药，其中A、B、R1、R2、D和E在此定义。用于治疗疾病的治疗方法，以及相关的组合物和药物也被披露。
• CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS
  申请人：Donde Yariv

  公开号：US20110082184A1

  公开（公告）日：2011-04-07

  A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed. Also disclosed herein are compounds comprising or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are also disclosed.

  本文披露了一种含有所述详细描述的基团的化合物或其药学上可接受的盐或前药。本文还披露了包括其衍生物或药学上可接受的盐、四唑或所述结构的化合物的前药在内的化合物，所述衍生物在本文中有详细描述。本文还披露了治疗疾病或病况，包括青光眼和眼内压升高的方法。还披露了与其相关的药物制剂的组合物和制造方法。
• Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
  申请人：Allergan, Inc.

  公开号：US07863319B2

  公开（公告）日：2011-01-04

  A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed. Also disclosed herein are compounds comprising or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are also disclosed.

  本文披露了一种化合物，包括或其药物可接受的盐或前药，具有此处详细描述的基团。本文还披露了化合物，包括其衍生物或药物可接受的盐、四唑或结构化合物或其衍生物的前药，所述衍生物在此处详细描述。本文还披露了治疗疾病或症状的方法，包括青光眼和眼内压升高。还披露了与此相关的药物组成和制造方法。